Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of remimazolam for general anesthesia

Trial Profile

A Phase I study of remimazolam for general anesthesia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 17 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remimazolam (Primary)
  • Indications General anaesthesia
  • Focus Adverse reactions
  • Most Recent Events

    • 17 May 2018 According to a PAION media release, this trial is expected to start in the second half of 2018 which can be expected to be the only necessary outstanding trial for filing for market approval in Europe based on the Scientific Advice obtained from the European Medicines Agency (EMA) in January 2018.
    • 23 Mar 2017 New trial record
    • 16 Mar 2017 According to a PAION media release, this trial will determine the number of patients required for a EU Phase III study (see profile 259255). Company expects to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top